Skip to main content
SpringerLink
Log in

Haploidentical Transplantation

  • Chapter
Advances in Allogeneic Hematopoietic Stem Cell Transplantation

Part of the book series: Cancer Treatment and Research ((CTAR,volume 101))

Abstract

The majority of patients who could benefit from allogeneic stem cell transplantation (allo-SCT) will not have an HLA-matched sibling donor (MSD) to create access to potentially curative therapy. Pioneering efforts by clinical investigatorshave now made alternative sources of allogeneic stem cells a possibility (-). Currently, access to allo-SCT is available through three sources, which include: 1) half-matched family members, 2) adult volunteer unrelated donors, and 3) related or unrelated umbilical cord blood units (CBU). All alternative donors are mismatched with the single exceptionof a MSD CBU. While there are availability and logistical differences between these alternative donors, a clear preference in choosing an alternative donor for transplantation awaits prospective randomized trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. O’Reilly RJ, Dupont B, Pahwa S, et al. Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. N Engl J Med 1977;297: 1311–1318.

    CAS  Google Scholar 

  2. Hansen JA, Clift RA, Thomas ED, et al. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 1980;303: 565–567.

    PubMed  CAS  Google Scholar 

  3. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985;313: 765–771.

    PubMed  CAS  Google Scholar 

  4. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Donor Program. N Engl J Med 1993;328: 593–602.

    PubMed  CAS  Google Scholar 

  5. Henslee PJ, Byers VS, Jennings E, et al. A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts. Transplantation Proceedings 1989;21: 3004–3007.

    PubMed  CAS  Google Scholar 

  6. Wagner JE, Rosenthal J, Sweetman R, et al.Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996;88(3): 795–802.

    PubMed  CAS  Google Scholar 

  7. Kurtzberg J, Laughlin M, Graham M, et al. Placental Blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335: 157–166.

    PubMed  CAS  Google Scholar 

  8. Gluckman E, Vanderson R, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997;337: 373–381.

    PubMed  CAS  Google Scholar 

  9. Anasetti C, Amos D, Beatty PG, et al.. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989;320: 197–204.

    PubMed  CAS  Google Scholar 

  10. Davies SM, Ramsay NKC, Haake RJ, et al.. Comparison of engraftment in recipients of matched sibling or unrelated donor marrow allografts. Bone Marrow Transplant 1994;13: 51–57.

    PubMed  CAS  Google Scholar 

  11. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997;337: 373–381.

    PubMed  CAS  Google Scholar 

  12. Hows J, Bradley BA, Gore S, et al. on behalf of the International Marrow Unrelated Search and Transplant (IMUST) Study. Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplant 1993;12: 371–380.

    PubMed  CAS  Google Scholar 

  13. Ash RC, Horowitz MM, Gale RP, et al.. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T-cell depletion. Bone Marrow Transplant 1991;7: 443–452.

    PubMed  CAS  Google Scholar 

  14. Szydlo R, Goldman JM, Klein JP, et al.. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767–1777.

    PubMed  CAS  Google Scholar 

  15. Sullivan KM, Mori M, Sanders J, et al.. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant 1992;10 (Suppl 1): 127–134.

    PubMed  Google Scholar 

  16. Ochs L, Shu XO, Miller J, et al.. Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. Blood 1995;10: 3979–3986.

    Google Scholar 

  17. Kook H, Goldman F, Padley D, et al.. Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: immunophenotypic analysis and factors affecting the speed of recovery. Blood 1996;88: 1089–1097.

    PubMed  CAS  Google Scholar 

  18. Lamb LS, Henslee-Downey PJ, Hazlett L, et al. Phenotypic and functional reconstitution of peripheral blood lymphocytes following T-cell depleted bone marrow transplantation from partially mismatched related donors. Bone Marrow Transplant 1998; 21(5): 461–471.

    PubMed  Google Scholar 

  19. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T cell restriction specificity, function, and responsiveness. Adv Immunol 1979;27: 151–177.

    Google Scholar 

  20. Benacerraf B, McDevitt HO. Histocompatibility-linked immune response genes. Science 1972;175: 273–279.

    PubMed  CAS  Google Scholar 

  21. Bach FH, Sachs DH. Transplantation immunology. N Engl J Med 1987;317: 489–492.

    PubMed  CAS  Google Scholar 

  22. van Rood JJ. The impact of the HLA system in clinical hematology. Blut 1989;59: 214–220.

    PubMed  Google Scholar 

  23. Martin PJ. Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared with related donors. Bone Marrow Transplant 1991;8: 217–223.

    PubMed  CAS  Google Scholar 

  24. Theobald M. Allorecognition and graft-versus-host disease. Bone Marrow Transplant 1995;15: 489–498.

    PubMed  CAS  Google Scholar 

  25. Goulmy E, Schipper R, Pool J, et al.. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334(5): 281–285.

    PubMed  CAS  Google Scholar 

  26. Keever CA, Leong N, Cunningham I, et al.. HLA-B44-directed cytotoxic T cells associated with acute graft-versus-host disease following unrelated bone marrow transplantation. Bone Marrow Transplant 1994;14: 137–145.

    PubMed  CAS  Google Scholar 

  27. Baxter-Lowe LA. Molecular techniques for typing unrelated donors: potential impact of molecular typing disparity on donor selection. Bone Marrow Transplant 1995;14(Suppl 4): 542–550.

    Google Scholar 

  28. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of Class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med 1998;339: 1177–1185.

    PubMed  CAS  Google Scholar 

  29. Kaufman R. A generalized HLA prediction model for related donor matches. Bone Marrow Transpl 1996;17: 1013–1020.

    CAS  Google Scholar 

  30. Vowels M, Honeyman M, Ziegler J, White L, Doran T, Lane J, Lam-Po-Tang R. Searches for matched and closely matched marrow donors undertaken in a paediatric unit. Transplant Proc 1990;22: 2171.

    PubMed  CAS  Google Scholar 

  31. Stroncek D, Bartsch G, Perkins HA, et al.. The National Marrow Donor Program. Transfusion 1993;33: 567–577.

    PubMed  CAS  Google Scholar 

  32. Rubinstein P, Rosenfield RE, Adamson JW, Stevens CE. Stored placental blood for unrelated bone marrow reconstitution. Blood 1993;81: 1679–1690.

    PubMed  CAS  Google Scholar 

  33. Sonnenberg FA, Eckman MH, Pauker SG. Bone marrow donor registries: the relation between registry size and probability of finding complete and partial matches. Blood 1989;74: 2569–2578.

    PubMed  CAS  Google Scholar 

  34. Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 1995;60(8): 778–783.

    PubMed  CAS  Google Scholar 

  35. Petersdorf EW, Longton GM, Anasetti C, et al.. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995;88: 1606–1613.

    Google Scholar 

  36. Speiser DE, Loliger CC, Siren MK, Jeannet M. Pretransplant cytotoxic donor T-cell activity specific to patient HLA class I antigens correlating with mortality after unrelated BMT. Br J Haematol 1996;93: 935–939.

    PubMed  CAS  Google Scholar 

  37. Martin PJ. The role of donor lymphoid cells in allogeneic marrow engraftment. Bone Marrow Transplant 1990;6: 283–289.

    PubMed  CAS  Google Scholar 

  38. Kernan NA, Flomenberg N, Dupont B, O’Reilly RJ. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia: identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation 1987;43(6): 842–847.

    PubMed  CAS  Google Scholar 

  39. O’Reilly RJ, Collins NH, Kernan NA, et al.. Transplantation of marrow depleted T cells by soybean lectin agglutination and E-rosette depletion: major histocompatibility complex-related graft resistance in leukemic transplant patients. Transplant Proc 1985;17: 455–459.

    Google Scholar 

  40. Henslee-Downey PJ, Parrish RS, Macdonald JS, et al.. Combined in vitro and in vivo T-lymphocyte depletion for the control of graft-versus-host disease following haplo-identical marrow transplant. Transplantation 1996;61(5): 738–745.

    PubMed  CAS  Google Scholar 

  41. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al.. Use of partially mismatched related donors extend access to allogeneic marrow transplant. Blood 1997; 89(10): 3864–3872.

    PubMed  CAS  Google Scholar 

  42. O’Reilly R, Hanson JA, Kurtzberg J, et al. Allogeneic marrow transplants: approaches for the patient lacking a donor. Hematology 1996, Eds: Schechter GP and McArthur JR, The American Society of Hematology, Seattle: 1996, 132–146.

    Google Scholar 

  43. Polchi P, Lucarelli G, Galimberti M, et al.. Haploidentical bone marrow transplantation from mother to child with advanced leukemia. Bone Marrow Transplant 1995; 16: 529–535.

    PubMed  CAS  Google Scholar 

  44. Nemunaitis J. Overview of the role of hematopoietic growth factors in bone marrow transplant recovery and bone marrow transplant failure. Support Care Cancer 1994; 2(6): 374–376.

    PubMed  CAS  Google Scholar 

  45. Molina L, Chabannon C, Viret F, et al.. Granulocyte colony-stimulating factor-mobilized allogeneic peripheral blood stem cells for rescue graft failure after allogeneic bone marrow transplantation in two patients with acute myeloblastic leukemia in first complete remission. Blood 1995; 85: 1678–1679.

    PubMed  CAS  Google Scholar 

  46. Godder KT, Abhyankar SH, Lamb LS, et al.. Donor leukocyte infusion for treatment of graft rejection post partially mismatched related donor bone marrow transplant. Bone Marrow Transplant 1998; 22: 111–113.

    PubMed  CAS  Google Scholar 

  47. Zecca M, Perotti C, Marradi P, et al.. Recombinant human G-CSF-mobilized peripheral blood stem cells for second allogeneic transplant after bone marrow graft rejection in children. Br J Haematol 1996; 92: 432–434.

    PubMed  CAS  Google Scholar 

  48. Trigg M, Gingrich R, Goeken N, et al.. Low rejection rate when using unrelated or haploidentical donors for children with leukemia undergoing marrow transplantation. Bone Marrow Transplant 1989;4(4): 431–437.

    PubMed  CAS  Google Scholar 

  49. Champlin RE, Ho WG, Mitsuyasu R, et al.. Graft failure and leukemia relaspe following T lymphocyte-depleted bone marrow transplants: effect of intensification of immunosuppressive conditioning. Transplant Proc 1987;19(1): 2616–2619.

    PubMed  CAS  Google Scholar 

  50. Sondel PM, Bozdech MJ, Trigg ME, et al.. Additional immunosuppression allows engraftment following HLA-mismatched T cell-depleted bone marrow transplantation for leukemia. Transplant Proc 1985; 17: 460–461.

    Google Scholar 

  51. Henslee PJ, Byers VS, Jennings CD, et al.. A new approach to the prevention of graft-versus-host disease using Xomazyme-H65 following histo-incompatible partially T-depleted marrow grafts. Transplant Proc 1989;21: 3004–3007.

    PubMed  CAS  Google Scholar 

  52. Henslee-Downey PJ, Romond E, Harder E, et al.. Successful engraftment and control of graft-versus-host disease following 3-antigen mismatched haploidentical marrow transplant. Blood 1991;78(Suppl 10): 231a.

    Google Scholar 

  53. Aversa F, Tabilio A, Terenzi A, et al.. Successful engraftment of T-cell-depleted haploidentical “three loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994;84(11): 3948–3955.

    PubMed  CAS  Google Scholar 

  54. Oakhill A, Pamphilon DH, Potter MN, et al.. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukeaemia in second remission. Br J Haematol 1996; 94: 574–578.

    PubMed  CAS  Google Scholar 

  55. Lee C, Brouillette M, Hazlett L, et al.. Comparison of engraftment and acute GvHD following transplantation or partially mismatched grafts T cell depleted with OKT3 or T10B9 monoclonal antibody. J Hematother 1997; 6(4): 395.

    Google Scholar 

  56. Henslee-Downey PJ, Lee CG, Hazlett LJ, et al. Rare failure to engraft following haploidentical T-cell depleted marrow transplantation using enhanced host immunoablation and OKT3 graft purging. Experimental Hematol 1997;25(8): 183a.

    Google Scholar 

  57. Aversa F, Martelli MM, Reisner Y. Use of stem cells from mismatched related donors. Curr Opin Hematol 1997;4(6): 419–422.

    PubMed  CAS  Google Scholar 

  58. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998;339: 1186–1193.

    PubMed  CAS  Google Scholar 

  59. Martin PJ, Hansen JA, Torok-Storb B, et al.. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988;3: 445–456.

    PubMed  CAS  Google Scholar 

  60. Smith CV, Suzuki T, Guzzetta PC, et al.. Bone marrow transplantation in miniature swine: IV. Development of myeloablative regimens that allow engraftment across major histocompatibility barriers. Transplantation 1993;56(3): 541–549.

    PubMed  CAS  Google Scholar 

  61. Patterson J, Prentice HG, Brenner MK, et al.. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br. J Haematol 1986;63: 221–230.

    PubMed  CAS  Google Scholar 

  62. Guyotat D, Dutou L, Erhsam A, et al.. Graft rejection after T cell-depleted marrow transplantation. Role of fractionated irradiation. Br J Haematol 1987;65: 499–507.

    PubMed  CAS  Google Scholar 

  63. van Os R, Konings AW. Compromising effect of low dose-rate total body irradiation of allogeneic bone marrow engraftment. Int J Radiat Biol 1993; 64(6): 761–770.

    PubMed  Google Scholar 

  64. Slavin S, Naparstek E, Aker M, et al.. The use of total lymphoid irradiation for prevention of rejection of T-lymphocyte depleted bone marrow allografts in non-malignant hematologic disorders. Transplant Proc 1989;21: 3053–3054.

    PubMed  CAS  Google Scholar 

  65. James ND, Apperley JF, Kam KC, et al.. Total lymphoid irradiation preceding bone marrow transplantation for chronic myeloid leukaemia. Clin Radiology 1989;40: 195–198.

    CAS  Google Scholar 

  66. Soiffer RJ, Mauch P, Tarbell NJ, et al.. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T-cell-depleted allogeneic marrow. Bone Marrow Transplant 1991;7(1): 23–33.

    PubMed  CAS  Google Scholar 

  67. Terenzi A, Lubin I, Lapidot T, et al.. Enhancement of T cell-depleted bone marrow allografts in mice by thiotepa. Transplantation 1990;20: 717–720.

    Google Scholar 

  68. Mackinnon S, Barnett L, Bourhis JH, et al.. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 1992;80(12): 3235–3241.

    PubMed  CAS  Google Scholar 

  69. Lapidot T, Terenzi A, Singer TS, et al.. Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood 1989;73(7): 2025–2032.

    PubMed  CAS  Google Scholar 

  70. Cahn JY, Herve P, Flesch M, et al.. Marrow transplantation from HLA non-identical family donors for the treatment of leukaemia: a pilot study of 15 patients using additional immunosuppression and T-cell depletion. Br J Haematol 1988;69: 345–349.

    PubMed  CAS  Google Scholar 

  71. Fischer A, Blanche S, Veber F, et al.. Prevention of graft failure by an anti-HLFA-1 monoclonal antibody in HLA-mismatched bone marrow transplantation. Lancet 1986; 2(8515): 1058–1061.

    PubMed  CAS  Google Scholar 

  72. Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies: results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994;13(5): 597–611.

    PubMed  CAS  Google Scholar 

  73. Kernan NA, Emanuel D, Castro-Malaspina H, et al.. Posttransplant immunosuppression with antithymocyte globulin and methylprednisolone prevents immunologically mediated graft failure following a T-cell depleted marrow transplant. Blood 1989;74(Suppll): 123a.

    Google Scholar 

  74. Malilay G P, Sevenich EA, Condie RM, Filipovich AH. Prevention of graft rejection in allogeneic bone marrow transplantation: I. Preclinical studies with antithymocyte globulins. Bone Marrow Transplant 1989;4: 107–112.

    PubMed  CAS  Google Scholar 

  75. Lee C, Henslee-Downey PJ, Brouillette M, et al.. Comparison of OKT3 and T10B9 for ex vivo T-cell depletion of partially mismatched related donor bone marrow transplants. Blood 1995;86 (10Suppll): 625a.

    Google Scholar 

  76. Terenzi A, Aristei C, Chionne F, et al.. Preliminary results of fludarabine as an immunosuppressor in bone marrow transplantation conditioning. Bone Marrow Transplant 1996;17(1):abstr 89.

    Google Scholar 

  77. Schultz KR, Ratanatharathorn V, Abella E, et al.. Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens. Bone Marrow Transplant 1994;13: 817–822.

    PubMed  CAS  Google Scholar 

  78. Godder K, Pati AR, Abhyankar S, et al.. Partially mismatched related donor transplants as salvage therapy for patients with refractory leukemia who relapse post-BMT. Bone Marrow Transplant 1996;17: 49–53.

    PubMed  CAS  Google Scholar 

  79. McGuirk J, Godder K, Pati AR, et al.. Salvage of relapsed acute myelogenous leukemia post-transplant using a partially mismatched related donor for second bone marrow transplant. Blood 1996;88 (10 Suppl 1): 269a.

    Google Scholar 

  80. Sondel PM, Hank JA, Trigg ME, et al.. Transplantation of HLA-haploidentical T cell-depleted marrow for leukemia: autologous marrow recovery with specific immune sensitization to donor antigens. Exp Hematol 1986;14: 278–286.

    PubMed  CAS  Google Scholar 

  81. Reisner Y, Kapoor N, Kirkpatrick D, et al.. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red cells. Blood 1983;61: 341–348.

    PubMed  CAS  Google Scholar 

  82. Reisner Y, Kapoor N, Kirkpatrick D, et al.. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981; 2(8242): 327–331.

    PubMed  CAS  Google Scholar 

  83. Matthay KK, Wara DW, Ammann AJ, et al.. Mismatched bone marrow transplantation using soybean agglutinin processed T-cell depleted marrow. In Progress in Bone Marrow Transplantation, Eds: Gale RP, Champlin RE; Alan R Liss, Inc., New York: 1987, 343–351.

    Google Scholar 

  84. Peters C, Balthazor M, Shapiro E, et al.. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996;87: 4894–4902.

    PubMed  CAS  Google Scholar 

  85. Prentice HG, Blacklock HA, Janossy G, et al.. Use of anti-T cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukemia. Lancet 1982; l(8274): 700–703.

    Google Scholar 

  86. Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunology Today 1995;16(9): 437–440.

    PubMed  CAS  Google Scholar 

  87. Reisner Y, Rachamim N, Bachar-Lustig E, et al.. Human CD34 stem cells exhibit potent veto activity in vitro: relevance to’ mega dose’ stem cell transplants in mismatched leukemia patients. Blood 1996;88(10Suppll): 298a.

    Google Scholar 

  88. Yaeger AM, Anasetti C, Chauncey T, et al.. Transplantation of positively selected CD34+ bone marrow and mobilized peripheral blood cells from haploidentical related donors for high-risk hematologic malignancies. Blood 1996;88(10Suppl2): 281b.

    Google Scholar 

  89. Mogul MJ, Forte KJ, Holland HK, et al.. Steroid-refractory cutaneous graft-versus-host disease after transplantation of haploidentical parental CD34+ cells in children with Down’s Syndrome and recurrent acute leukemia. J Ped Hem/One 1997; 19(1): 142–144.

    CAS  Google Scholar 

  90. Fujimori Y, Kanamaru A, Hashimoto N, et al.. Second transplantation with CD34+ bone marrow cells selected from a two-loci HLA-mismatched sibling for a patient with chronic myeloid leukemia. Brit J Haematol 1996;94: 123–125.

    CAS  Google Scholar 

  91. Russell JA, Desai S, Herbut B, et al.. Partially mismatched blood cell transplants for high-risk hematologic malignancy. Bone Marrow Transplant 1997; 19: 861–866.

    PubMed  CAS  Google Scholar 

  92. Abhyankar SH, Geier SS, Parrish R, et al.. Effect of crossmatch reactions and HLA typed cell panel antibody response on engraftment using plasmapheresis and Prosorba column absorption during partially mismatched related donor BMT. Blood 1995;86(10 Suppl l): 564a.

    Google Scholar 

  93. Bishop MR, Henslee-Downey PJ, Anderson JR, et al.. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors. Bone Marrow Transplant 1996;18: 747–753.

    PubMed  CAS  Google Scholar 

  94. Lamb LS, Szafer F, Henslee-Downey PJ, et al.. Characterization of acute bone marrow graft rejection in T cell-depleted, partially mismatched related donor Bone marrow transplantation. Exp Hematol 1995;23: 1595–1600.

    PubMed  Google Scholar 

  95. Lamb L, Gee A, Parrish R, et al.. Acute rejection of marrow grafts in patients transplanted from a partially mismatched related donor: clinical and immunologic characteristics. Bone Marrow Transplant 1996;17: 1021–1027.

    PubMed  Google Scholar 

  96. Donohue J, Homge M, Kernan NA. Characterization of cells emerging at the time of graft failure after bone marrow transplantation from an unrelated marrow donor. Blood 1993;82(3): 1023–1029.

    PubMed  CAS  Google Scholar 

  97. Beatty PG, Hansen JA, Longton GM, et al.. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic maligancies. Transplantation 1991;51: 443–447.

    PubMed  CAS  Google Scholar 

  98. Gajewski JL, Ho WG, Feig SA, et al.. Bone marrow transplantation using unrelated donors for patients with advanced leukemia or bone marrow failure. Transplantation 1990;50: 244–249.

    PubMed  CAS  Google Scholar 

  99. McGlave P, Bartsch G, Anasetti C, et al.. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993;81: 543–550.

    PubMed  CAS  Google Scholar 

  100. Balduzzi A, Gooley T, Anasetti C, et al.. Unrelated donor marrow transplantation in children. Blood 1995;86: 3247–3256.

    PubMed  CAS  Google Scholar 

  101. Davies SM, Wagner JE, Shu X-O, et al.. Unrelated donor bone marrow transplantation for children with acute leukemia. J Clin Oncol 1997;15: 557–565.

    PubMed  CAS  Google Scholar 

  102. McGlave P. Unrelated donor transplant therapy for chronic myelogenous leukemia. Hem/One Clin of N Amer 1998;12(1): 93–105.

    CAS  Google Scholar 

  103. O’Reilly RJ, Kernan N, Cunningham I, et al.. Soybean lectin agglutination and E-rosette depletion for removal of T-cells from HLA-identical and non-identical grafts administered for the treatment of leukemia. In T-Cell Depletion in Allogeneic Bone Marrow Transplantation, Eds: Martelli MF, Grignani F, Reisner Y; Ares-Serono Symposia, Rome Italy: 1988, 123–129.

    Google Scholar 

  104. Martin PJ, Kernan NA. T-cell depletion for the prevention of graft-vs.-host disease. In Graft-vs.Host Disease: Immunology, Pathophysiology, and Treatment, Eds: Burkoff SJ, Deeg HJ, Ferrara J, Atkinson K; Marcel Dekker, New York,NY: 1990, 371–387.

    Google Scholar 

  105. Horowitz MM, Gale RP, Sondel PM, et al.. Graft-versus-leukemia reactions after bone marrow transplantation.Blood 1990;75: 555–562.

    PubMed  CAS  Google Scholar 

  106. Marmont AM, Horowitz MM, Gale RP, et al.. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78(8): 2120–2130.

    PubMed  CAS  Google Scholar 

  107. Drobyski WR, Ash RC, Casper JT, et al.. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia.Blood 1994;83(7): 1980–1987.

    PubMed  CAS  Google Scholar 

  108. Hessner MJ, Endean DJ, Casper JT, et al.. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995;86(10): 3987–3996.

    PubMed  CAS  Google Scholar 

  109. Speiser DE, Hermans J, van Biezen A, et al.. Haploidentical family member transplants for patients with chronic myeloid leukaemia: a report of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997;19: 1197–1203.

    PubMed  CAS  Google Scholar 

  110. Lee C, Henslee-Downey PJ, Christiansen N, et al.: Consistent prompt engraftment and low risk of acute graft-versus-host disease following haploidentical transplant. J Hematotherapy, 1998;7(3): 274.

    Google Scholar 

  111. Lowenberg B, Wagemaker E, van Beckkum DW, et al.. Graft-versus-host disease following transplantation of “one log” versus “two log” T-lymphocyte depleted bone marrow from HLA-identical donors. Bone Marrow Transplant 1986;1: 133–140.

    PubMed  CAS  Google Scholar 

  112. Kernan NA, Collins NH, Juliano L, et al.. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-versus-host disease. Blood 1986;68: 770–773.

    PubMed  CAS  Google Scholar 

  113. Atkinson K, Farrelly H, Cooley M, et al.. Human marrow T cell dose correlates with severity of subsequent acute graft-versus-host disease. Bone Marrow Transplant 1987;2: 51–57.

    PubMed  CAS  Google Scholar 

  114. Ash RC, Casper JT, Chitambar CR, et al.. Successful allogeneic transplantation of T-cell depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 1990;322: 485–494.

    PubMed  CAS  Google Scholar 

  115. Casper J, Camitta B, Truitt R, et al.. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 1995;85(9): 2354–2363.

    PubMed  CAS  Google Scholar 

  116. Cullis JO, Szydlo RM, Cross NC, et al.. Matched unrelated donor bone marrow transplantation for chronic myeloid leukemia in chronic phase: comparison of ex vivo and in vivo T-cell depletion. Bone Marrow Transplant 1993;11 (Suppll): 107–111.

    PubMed  Google Scholar 

  117. Henslee-Downey PJ, Gee AP, Godder K, et al.. Minimal risk of graft versus host disease following haploidentical but partially mismatched related donor bone marrow transplantation. Exp Hematol 1994;22: 716a.

    Google Scholar 

  118. Bunin NJ, Casper JT, Lawton C, et al.. Allogeneic marrow transplantation using T cell depletion for patients with juvenile chronic myelogeneous leukemia without HLA-identical siblings. Bone Marrow Transplant 1992;9: 119–122.

    PubMed  CAS  Google Scholar 

  119. Fleming DR, Henslee-Downey PJ, Romond EH, et al.. Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study. Bone Marrow Transplant 1996;17: 917–922.

    PubMed  CAS  Google Scholar 

  120. Lee C, Brouillete M, Lamb L, et al.. Use of a closed system for V ab-positive T-cell depletion of marrow for use in partially mismatched related donor transplantation. In Progress in Clinical and Biological Research, Eds, Gee A, Gross S, Worthington-White D; Wiley Liss, New York, NY: 1994, 523–532.

    Google Scholar 

  121. Nademanee A, Schmidt GM, Parker P, et al.. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporin, methotrexate, and prednisone. Blood 1995;86: 1228–1234.

    PubMed  CAS  Google Scholar 

  122. Soiffer RJ, Mauch P, Fairclough D, et al.. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA non-identical related donors. Biol Bld and Mar Transplant 1997; 3: 11–17.

    CAS  Google Scholar 

  123. Roy J, McGlave PB, Filipovich AH, et al.. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant 1992;10: 77–82.

    PubMed  CAS  Google Scholar 

  124. Hings IM, Severson R, Filipovich AH, et al.. Treatment of moderate and severe acute GvHD after allogeneic bone marrow transplantation. Transplantation 1994;58: 437–442.

    PubMed  CAS  Google Scholar 

  125. Busca A, Anasetti C, Anderson G, et al.. Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. Blood 1994;83(10): 3077–3084.

    PubMed  CAS  Google Scholar 

  126. Marks DI, Cullis JO, Ward KN, et al.. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first 2 years. Ann Intern Med 1993;119: 207–214.

    PubMed  CAS  Google Scholar 

  127. Enright H, Davies S, McGlave P. Bone marrow transplantation for chronic myelogenous leukemia: clinical outcomes. Clin Transpl 1994;283–293.

    Google Scholar 

  128. Gerritsen EJ, Stam ED, Hermans J, et al.. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996;18: 377–382.

    PubMed  CAS  Google Scholar 

  129. Bhatia S, Ramsay NK, Steinbuch M, et al.. Malignant neoplasms following bone marrow transplantation. Blood 1996;87(9): 3633–3639.

    PubMed  CAS  Google Scholar 

  130. Godder K, Pati AR, Abhyankar SH, et al.. De novo chronic graft-versus-host disease presenting as hemolytic anemia following partially mismatched related donor bone marrow transplant. Bone Marrow Transplant 1997; 19: 813–817.

    PubMed  CAS  Google Scholar 

  131. Schultz KR, Green GJ, Wensley D, et al.. Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood 1994;84(9): 3212–3220.

    PubMed  CAS  Google Scholar 

  132. Atkinson K, Farewell V, Storb R, et al.. Analysis of late infections after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. Blood 1982;60(3): 714–720.

    PubMed  CAS  Google Scholar 

  133. Riddell SR, Watanabe K, Goodrich J, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257: 238–241.

    PubMed  CAS  Google Scholar 

  134. Walter E, Greenberg P, Gilbert M, et al.. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;16: 1038–1044.

    Google Scholar 

  135. Rooney CM, Smith CA, Ng CYC, et al.. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345: 9–13.

    PubMed  CAS  Google Scholar 

  136. Heslop HE, Ng CY, Li C, et al.. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;5: 551–555.

    Google Scholar 

  137. Kline RM, Stiehm ER, and Cowan MJ. Bone marrow’ boosts’ following T cell-depleted haploidentical bone marrow transplantation. Bone Marrow Transplant 1996; !7(4): 543–548.

    Google Scholar 

  138. Sullivan KM, Kopecky Jocom J, Fisher L, et al.. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990;323: 705–712.

    PubMed  CAS  Google Scholar 

  139. Slavin S, Naparstek E, Nagler A, et al.. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995;23(14): 1553–1562.

    PubMed  CAS  Google Scholar 

  140. van Rhee F, Lin F, Cullis JO, et al.. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994;11: 3377–3383.

    Google Scholar 

  141. Pati AR, Godder K, Parrish R, et al. Pre-emptive therapy with donor leukocyte infusions to prevent relapse following partially mismatched related donor bone marrow transplantation. Blood 1996;88 (10Suppll): 259a.

    Google Scholar 

  142. Hansen JA, Gooley TA, Martin PJ, et al.. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962–968.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Richland Memorial Hospital Center for Cancer Treatment and Research, South Carolina Cancer Center University of South Carolina and Palmetto, Columbia, South Carolina, USA

    P. Jean Henslee-Downey M.D.

Authors
  1. P. Jean Henslee-Downey M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northwestern University Medical Center, Chicago, USA

    Richard K. Burt  & Mary M. Brush  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Henslee-Downey, P.J. (1999). Haploidentical Transplantation. In: Burt, R.K., Brush, M.M. (eds) Advances in Allogeneic Hematopoietic Stem Cell Transplantation. Cancer Treatment and Research, vol 101. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4987-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4987-1_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7264-6

  • Online ISBN: 978-1-4615-4987-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation